Metopimazine is primarily metabolized by a liver amidase in humans.

Autor: Busby RW; Neurogastrx, Inc., Woburn, Massachusetts, USA., Cai X; QPS, Newark, Delaware, USA., Yang S; QPS, Newark, Delaware, USA., Ramos L; QPS, Newark, Delaware, USA., Venkatarangan L; QPS, Newark, Delaware, USA., Shen H; QPS, Newark, Delaware, USA., Wax S; Neurogastrx, Inc., Woburn, Massachusetts, USA., Sadeque AJM; QPS, Newark, Delaware, USA., De Colle C; Neurogastrx, Inc., Woburn, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Pharmacology research & perspectives [Pharmacol Res Perspect] 2022 Feb; Vol. 10 (1), pp. e00903.
DOI: 10.1002/prp2.903
Abstrakt: Metopimazine (MPZ) is a peripherally restricted, dopamine D2 receptor antagonist used for four decades to treat acute nausea and vomiting. MPZ is currently under clinical investigation for the treatment of gastroparesis (GP). MPZ undergoes high first-pass metabolism that produces metopimazine acid (MPZA), the major circulating metabolite in humans. Despite a long history of use, the enzymes involved in the metabolism of MPZ have not been identified. Here we report a series of studies designed to identify potential MPZ metabolites in vitro, determine their clinical relevance in humans, and elucidate the enzymes responsible for their formation. The findings demonstrated that the formation of MPZA was primarily catalyzed by human liver microsomal amidase. Additionally, human liver cytosolic aldehyde oxidase (AO) catalyzes the formation of MPZA, in vitro, although to a much lesser extent. Neither cytochrome P450 enzymes nor flavin-monooxygenases (FMO) were involved in the formation MPZA, although two minor oxidative pathways were catalyzed by CYP3A4 and CYP2D6 in vitro. Analysis of plasma samples from subjects dosed 60 mg of MPZ verified that these oxidative pathways are very minor and that CYP enzyme involvement was negligible compared to microsomal amidase/hydrolase in overall MPZ metabolism in humans. The metabolism by liver amidase, an enzyme family not well defined in small molecule drug metabolism, with minimal metabolism by CYPs, differentiates this drug from current D2 antagonists used or in development for the treatment of GP.
(© 2021 Neurogastrx Inc. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje